RHA® 4 NLF Cannula
A Randomized, Controlled, Single-blinded, Within-subject (Split-face), Multicenter, Prospective Clinical Study to Evaluate the Effectiveness and Safety of Using the Dermal Filler RHA®4 Injected With a Cannula or With a Sharp Needle for the Treatment of Moderate to Severe Nasolabial Folds
Sponsor: Teoxane SA
This NA trial investigates Aging and Nasolabial Fold and is currently completed. Teoxane SA leads this study, which shows 8 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Apr 2023 — Jul 2024 [monthly]
Completed NA
Status: Withheld → Completed · Phase: None → NA
-
Jul 2022 — Apr 2023 [monthly]
Withheld
-
Dec 2021 — Jul 2022 [monthly]
Withheld
▶ Show 3 earlier versions
-
Jun 2021 — Dec 2021 [monthly]
Withheld
-
May 2021 — Jun 2021 [monthly]
Withheld
-
Mar 2021 — May 2021 [monthly]
Withheld
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Teoxane SA
For direct contact, visit the study record on ClinicalTrials.gov .